A brief look at the evaluation of the development and effectiveness of cytotoxic chemotherapy in advanced non-small-cell lung cancer İleri evre küçük hücreli dişi akciǧer kanseri tedavisinde kemoterapinin son yillarda gelişim ve etkinliǧinin deǧerlendirilmesine kisa bir bakiş

Uzunoǧlu S., KARAGÖL H., Tanriverdi Ö., ÇİÇİN İ., Çaloǧlu M., KOÇAK Z.

Turk Onkoloji Dergisi, cilt.25, sa.2, ss.77-85, 2010 (Scopus) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 25 Sayı: 2
  • Basım Tarihi: 2010
  • Dergi Adı: Turk Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.77-85
  • Anahtar Kelimeler: New generation agents, Non-small-cell lung cancer, Systemic chemotherapy
  • Trakya Üniversitesi Adresli: Evet

Özet

Systemic chemotherapy for patients with advanced-stage non-small-cell lung cancer prolongs survival and palliates symptoms, when compared with the best supportive care alone. However, the results of standard cytotoxic regimens are not yet satisfactory. As the effectiveness in the treatment of refractory disease is low, it still remains critical to better understand and develop new treatment options for refractory disease. Within the second-line therapeutic approaches, there are new chemotherapeutic schemes as well as molecular-targeted treatment options that block the epidermal growth factor receptor or angiogenesis. Future research efforts should focus on identifying prognostic and predictive markers of benefit not only for the standard cytotoxic agents, but also for the new target-driven agents currently. © 2010 Association of Oncology.